Pharma-Bio Serv, Inc.
PBSV
$0.55
$0.07515.79%
| 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -43.99% | -40.20% | -28.99% | -18.80% | -12.48% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -43.99% | -40.20% | -28.99% | -18.80% | -12.48% |
| Cost of Revenue | -41.29% | -36.93% | -29.58% | -21.72% | -17.96% |
| Gross Profit | -50.34% | -48.16% | -27.43% | -10.56% | 3.79% |
| SG&A Expenses | -3.68% | -0.06% | 5.76% | 7.56% | 6.54% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -31.92% | -28.30% | -21.75% | -15.47% | -12.97% |
| Operating Income | -215.23% | -188.57% | -127.50% | -69.46% | -4.89% |
| Income Before Tax | -144.76% | -140.09% | -94.73% | -39.26% | 42.02% |
| Income Tax Expenses | -94.14% | -87.97% | -76.48% | -13.54% | 107.59% |
| Earnings from Continuing Operations | -159.35% | -154.93% | -100.42% | -45.64% | 30.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -159.35% | -154.93% | -100.42% | -45.64% | 30.16% |
| EBIT | -215.23% | -188.57% | -127.50% | -69.46% | -4.89% |
| EBITDA | -208.48% | -183.39% | -123.91% | -67.58% | -4.95% |
| EPS Basic | -159.47% | -155.11% | -100.53% | -45.82% | 30.14% |
| Normalized Basic EPS | -144.57% | -139.93% | -94.59% | -39.32% | 41.98% |
| EPS Diluted | -160.70% | -156.16% | -100.89% | -45.68% | 32.56% |
| Normalized Diluted EPS | -144.57% | -139.93% | -94.59% | -39.16% | 42.41% |
| Average Basic Shares Outstanding | -0.01% | -0.01% | 0.01% | 0.01% | -0.05% |
| Average Diluted Shares Outstanding | -0.07% | -0.08% | -0.04% | 0.04% | -0.07% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -2.68% | -2.82% | -240.13% | 0.84% | -0.62% |
